STOCK TITAN

Intercept Pharmaceuticals Inc - ICPT STOCK NEWS

Welcome to our dedicated news page for Intercept Pharmaceuticals (Ticker: ICPT), a resource for investors and traders seeking the latest updates and insights on Intercept Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Intercept Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Intercept Pharmaceuticals's position in the market.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.18%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.07%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.41%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.41%
Tags
none
Intercept Pharmaceuticals Inc

Nasdaq:ICPT

ICPT Rankings

ICPT Stock Data

794.69M
34.49M
3.13%
81.3%
24.24%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Morristown

About ICPT

we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.